This web app uses cookies to compile statistic information of our users visits. By continuing to browse the site you are agreeing to our use of cookies. If you wish you may change your preference or read about cookies

close
Are you looking for more examples of business models like this one?

Access to hundreds of business models

Embed code:

x
Copy the code below and embed it in yours to show this business model canvas in your website.

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited engineered CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq global market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS).